3,4-Dihydropyran is a heterocyclic compound with a six-membered ring containing one oxygen atom and a double bond. It is a colorless liquid that is used as a reagent in organic synthesis. It is particularly important in the synthesis of pyrans, which are important building blocks for many organic molecules. 3,4-dihydropyran can be synthesized by a variety of methods, including the Diels-Alder reaction and the ring-opening metathesis polymerization. It is studied due to its potential applications in pharmaceuticals, materials science, and agrochemicals. The compound exhibits a variety of biological activities, such as antimicrobial and anti-inflammatory effects, making it a promising lead compound for drug development.'
| ID Source | ID |
|---|---|
| PubMed CID | 8080 |
| CHEMBL ID | 3184439 |
| MeSH ID | M0199454 |
| Synonym |
|---|
| dihydro-2h-pyran |
| 2h-pyran, dihydro- |
| 3,4-dihydropyran |
| 2,3-dihydro-4h-pyran |
| .delta.2-dihydropyran |
| 2h-3,4-dihydropyran |
| nsc-57860 |
| dihydropyran |
| nsc57860 |
| 110-87-2 |
| wln: t6o butj |
| 5,6-dihydro-4h-pyran |
| pyran, 2,3-dihydro- |
| .delta.(sup2)-dihydropyran |
| nsc-73472 |
| nsc73472 |
| inchi=1/c5h8o/c1-2-4-6-5-3-1/h2,4h,1,3,5h |
| 3,4-dihydro-2h-pyran |
| 2h-pyran, 3,4-dihydro- |
| 3,4-dihydro-2h-pyran, 97% |
| D0555 |
| 2,3-dihydropyran |
| AKOS000121126 |
| NCGC00248323-01 |
| dihydropyrane |
| 2,3-dihydropyrane |
| NCGC00255086-01 |
| cas-110-87-2 |
| dtxcid4021426 |
| dtxsid6041426 , |
| tox21_301188 |
| 3,4-dihydro-2h-pyrane |
| STL146593 |
| nsc 57860 |
| einecs 203-810-4 |
| ai3-16497 |
| unii-t6v9n71ihx |
| dihydropyran (van) |
| 2,3-dihydropyran [un2376] [flammable liquid] |
| t6v9n71ihx , |
| un2376 |
| ec 203-810-4 |
| delta2-dihydropyran |
| BP-21473 |
| 3,4-dihdro-2h-pyrane |
| 3,4-dihydro-2 h-pyran |
| 2,3-dihydro-pyran |
| 3,4-dihydro-2-pyran |
| 3,4-dihydro-2-h-pyrane |
| 3,4-dihydropyrane |
| 3.4-dihydro-2h-pyran |
| 2,4-dihydropyran |
| 3,4- dihydro-2h-pyran |
| dihyropyran |
| 2,3-dihydro-4-h-pyran |
| 3,4dihydro-2h-pyran |
| 3,4-dihyro-2h-pyran |
| 3,4 - dihydro-2h-pyran |
| 3,4-dihydro-pyran |
| 3,4-dihydro-2h -pyran |
| dihyrdopyran |
| 3,4-dihydro 2h-pyran |
| 2,3dihydropyran |
| 3,4-dihydro-1h-pyran |
| 2,3-dihyropyran |
| 3,4-dihydro-[2h]-pyran |
| 3,4-dihydro-2-h-pyran |
| 3,4 dihydro-2h-pyran |
| 3, 4dihydro-2h-pyran |
| 3,4-dihydro-2h pyran |
| 2,3-dihydro-4h-pyrane |
| 4,5-dihydropyran |
| 3,4-dihydro(2h)pyran |
| STR01188 |
| CS-W013755 |
| pyran, dihydro- |
| 2,3-dihydro-.gamma.-pyran |
| 2-pyran, 3,4-dihydro- |
| 1,2-pyran, 3,4-dihydro- |
| dihydro-2h-pyran, 3,4- |
| dihydropyran [mi] |
| CHEMBL3184439 |
| mfcd00006558 |
| J-511179 |
| F0001-0228 |
| 3,4-dihydro-2h-pyran, purum, >=95.0% (gc) |
| Q419349 |
| AMY39440 |
| D78128 |
| EN300-26571 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 14.2680 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 24.3365 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1133201 | Antimicrobial activity against Microsporum canis at 0.4 umol/mL by broth microdilution method | 1978 | Journal of medicinal chemistry, Dec, Volume: 21, Issue:12 | Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors. |
| AID1133202 | Antimicrobial activity against Pseudomonas aeruginosa at 0.4 umol/mL by broth microdilution method | 1978 | Journal of medicinal chemistry, Dec, Volume: 21, Issue:12 | Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors. |
| AID1133200 | Antimicrobial activity against Epidermophyton floccosum at 0.4 umol/mL by broth microdilution method | 1978 | Journal of medicinal chemistry, Dec, Volume: 21, Issue:12 | Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors. |
| AID1133203 | Antimicrobial activity against Staphylococcus aureus at 0.4 umol/mL by broth microdilution method | 1978 | Journal of medicinal chemistry, Dec, Volume: 21, Issue:12 | Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors. |
| AID1133198 | Antimicrobial activity against Candida albicans at 0.4 umol/mL by broth microdilution method | 1978 | Journal of medicinal chemistry, Dec, Volume: 21, Issue:12 | Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors. |
| AID1133204 | Antimicrobial activity against Trichophyton mentagrophytes at 0.4 umol/mL by broth microdilution method | 1978 | Journal of medicinal chemistry, Dec, Volume: 21, Issue:12 | Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||